Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization
Pharmaceuticals · 16.11.2026 · 19 (11) · 1816
DOI: 10.3390/ph19111816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 16.11.2026. Verfasst von Motamarri V. N. L. Chaitanya und 4 weiteren Autor:innen. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Existing PCOS reviews largely catalogue natural products and reported molecular pathways. This structured critical review asks a different translational question: which constituents from weed, ruderal and invasive taxa remain credible candidates when target engagement, pharmacological direction, realistic exposure and safety are considered together.
Methods
PubMed/MEDLINE, Web of Science Core Collection and CAB Abstracts were searched from inception to 2 September 2026, with CABI resources used to verify weed status. Eligible pharmacological, pharmacokinetic and toxicological evidence was critically appraised using a T1–T4 mechanistic evidence hierarchy and evaluated for exposure plausibility, methodological quality and citation integrity.
Results
No positive mechanistic claim reached T3 or T4. Urtica dioica L. lignans demonstrably displace dihydrotestosterone from SHBG in vitro, but the predicted consequence for free androgen exposure in vivo remains untested; flavonoid aromatase effects are assay- and context-dependent; and several widely cited systemic mechanisms are not supported by current exposure data. Silybin exposure supports a narrower liver-directed hypothesis, whereas non-absorbed inulin-type fructans provide a luminal gut-axis case in which systemic exposure is not required. Mentha spicata L. provides a reproducible human endocrine signal but no defined active constituent or molecular target.
Conclusions
The principal barrier to clinical translation is not a shortage of activity signals but the absence of demonstrated in vivo target engagement, target-site pharmacokinetics and reproductive-safety qualification. No candidate currently clears all five gates. Silybum marianum flavonolignans and Cichorium intybus inulin-type fructans are therefore only provisionally prioritized for node-specific nonclinical development, while M. spicata is a mechanism-resolution research signal rather than a pharmacological lead. The framework prioritizes the experiments needed to establish development readiness; it does not infer PCOS-specific efficacy from the existing evidence.
Zitieren
APA
Chaitanya, M. V. N. L., Priya, P., Mittal, A., Dutta, S., & Sengupta, P. (2026). Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization. Pharmaceuticals, 19(11), 1816. https://doi.org/10.3390/ph19111816
Vancouver
Chaitanya MVNL, Priya P, Mittal A, Dutta S, Sengupta P. Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization. Pharmaceuticals. 2026;19(11):1816. doi:10.3390/ph19111816
BibTeX
@article{Chaitanya2026,
author = {Chaitanya, Motamarri V. N. L. and Priya, Priyanshu and Mittal, Amit and Dutta, Sulagna and Sengupta, Pallav},
title = {Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1816},
doi = {10.3390/ph19111816}
}
EUVIMED